| scholarly article | Q13442814 |
| P50 | author | James P. Allison | Q6140731 |
| Anne E Trumble | Q56891561 | ||
| Larry Norton | Q37644083 | ||
| P2093 | author name string | Stephen B Solomon | |
| Rebecca Waitz | |||
| Marcella Fassò | |||
| Elena N Petre | |||
| P2860 | cites work | Immunologic response to cryoablation of breast cancer | Q40446167 |
| In situ tumor ablation creates an antigen source for the generation of antitumor immunity | Q40550098 | ||
| In vivo destruction of tumor tissue by cryoablation can induce inhibition of secondary tumor growth: an experimental study | Q40808256 | ||
| Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. | Q41735884 | ||
| Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors | Q42051381 | ||
| Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. | Q42815729 | ||
| Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer | Q46252104 | ||
| Epitope landscape in breast and colorectal cancer. | Q51894674 | ||
| Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. | Q51976721 | ||
| Adoptive immunotherapy of breast cancer with lymph node cells primed by cryoablation of the primary tumor. | Q53599386 | ||
| Comparative immunological studies in rats following cryosurgery and surgical excision of 3-methylcholanthrene-induced primary autochthonous tumors. | Q54516265 | ||
| Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer | Q56903097 | ||
| Antitumor effects of residual tumor after cryoablation: the combined effect of residual tumor and a protein-bound polysaccharide on multiple liver metastases in a murine model | Q57105366 | ||
| Mechanisms of tissue injury in cryosurgery | Q57108848 | ||
| Synergy between In situ Cryoablation and TLR9 Stimulation Results in a Highly Effective In vivo Dendritic Cell Vaccine | Q58620026 | ||
| Enhanced tumor metastases in rats following cryosurgery of primary tumor | Q70451622 | ||
| Cryosurgical ablation of the normal ventral prostate plus adjuvant does not protect Copenhagen rats from Dunning prostatic adenocarcinoma challenge | Q73709122 | ||
| Control of regulatory T cell development by the transcription factor Foxp3 | Q27860489 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Enhancement of antitumor immunity by CTLA-4 blockade | Q28275730 | ||
| Investigation of the mechanism and the effect of cryoimmunology in the Copenhagen rat. | Q33945419 | ||
| Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer | Q34147128 | ||
| Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer | Q34210036 | ||
| Remission of Metastatic Lesions Following Cryosurgery in Prostatic Cancer: Immunologic Considerations | Q34225753 | ||
| Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity | Q34334817 | ||
| Prostate cancer in a transgenic mouse | Q34444393 | ||
| Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. | Q34657928 | ||
| CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. | Q36284594 | ||
| Comparison of cryoablation, radiofrequency ablation and high-intensity focused ultrasound for treating small renal tumours | Q36312844 | ||
| Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp | Q36375152 | ||
| SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade | Q36491182 | ||
| Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients | Q36498459 | ||
| Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. | Q36611772 | ||
| Cost analysis of open, laparoscopic, and percutaneous treatment options for nephron-sparing surgery | Q36649050 | ||
| Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. | Q36780750 | ||
| Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma | Q36853440 | ||
| Image-guided percutaneous cryoablation of renal tumors. | Q37028498 | ||
| Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablation | Q37268005 | ||
| Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses | Q37325106 | ||
| Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies | Q39828440 | ||
| CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells | Q40266751 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 430-439 | |
| P577 | publication date | 2011-11-22 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy | |
| P478 | volume | 72 |
| Q37509479 | A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling |
| Q41928232 | A Review of Immune Therapy in Cancer and a Question: Can Thermal Therapy Increase Tumor Response? |
| Q37658308 | Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas |
| Q34617627 | Beyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting |
| Q53028366 | Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer. |
| Q26992295 | CTLA-4 blockade in tumor models: an overview of preclinical and translational research |
| Q42214233 | CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection |
| Q38171573 | Cancer immunotherapy using tumor cryoablation |
| Q50100688 | Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here |
| Q38760734 | Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas |
| Q38665664 | Combined Blockade of T Cell Immunoglobulin and Mucin Domain 3 and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Results in Durable Therapeutic Efficacy in Mice with Intracranial Gliomas |
| Q56892705 | Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer |
| Q39738697 | Controlling melanoma at local and systemic levels: is a combination of ablative therapy and immunotherapy the way forward? |
| Q35184986 | Cryo-ablation improves anti-tumor immunity through recovering tumor educated dendritic cells in tumor-draining lymph nodes |
| Q90681174 | Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors |
| Q36597502 | Cryoablation and Meriva have strong therapeutic effect on triple-negative breast cancer |
| Q64051980 | Cryoablation and immunotherapy: an overview of evidence on its synergy |
| Q60045474 | Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy |
| Q34288183 | Cryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates HER2/neu immunity. |
| Q37340661 | Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy |
| Q51556518 | Defeating Cancers' Adaptive Defensive Strategies Using Thermal Therapies: Examining Cancer's Therapeutic Resistance, Ablative, and Computational Modeling Strategies as a means for Improving Therapeutic Outcome. |
| Q55257766 | Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma. |
| Q89356407 | Developing a Roadmap for Interventional Oncology |
| Q34919077 | Elimination of metastatic melanoma using gold nanoshell-enabled photothermal therapy and adoptive T cell transfer |
| Q38184650 | Emerging immunotherapy strategies in breast cancer |
| Q36723747 | Enhanced Anti-Tumor Efficacy through a Combination of Integrin αvβ6-Targeted Photodynamic Therapy and Immune Checkpoint Inhibition |
| Q35178939 | Enhancement of T cell recruitment and infiltration into tumours. |
| Q24629841 | Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma |
| Q37701177 | Ginsenoside Rh2 enhances the antitumor immunological response of a melanoma mice model |
| Q60948054 | HLA-A2-Restricted Epitopes Identified from MTA1 Could Elicit Antigen-Specific Cytotoxic T Lymphocyte Response |
| Q38596007 | Harnessing the immunomodulatory effect of thermal and non-thermal ablative therapies for cancer treatment |
| Q34205626 | Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10. |
| Q64091327 | Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges |
| Q38816839 | Immune Checkpoint Therapies in Prostate Cancer |
| Q42690545 | Immuno-thermal ablations - boosting the anticancer immune response |
| Q90009896 | Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors |
| Q30354580 | Immunological effect of local ablation combined with immunotherapy on solid malignancies. |
| Q34444291 | Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis |
| Q47217599 | Immunomodulation characteristics by thermal ablation therapy in cancer patients |
| Q36841621 | Immunomodulatory therapy for melanoma: ipilimumab and beyond |
| Q52592731 | Immunotherapy Plus Cryotherapy: Potential Augmented Abscopal Effect for Advanced Cancers. |
| Q90229263 | Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper |
| Q38180749 | Immunotherapy for malignant pleural mesothelioma. Current status and future prospects |
| Q38413904 | Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some |
| Q49571153 | Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop |
| Q89721163 | Induction of antitumor immunity in mice by the combination of nanoparticle-based photothermolysis and anti-PD-1 checkpoint inhibition |
| Q58559604 | Interventional Oncology: Treatment of primary liver tumors and liver metastases. Part II: non-nuclear techniques |
| Q39325230 | Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer |
| Q38069640 | Ipilimumab in prostate cancer |
| Q26822491 | Local tumour ablative therapies: opportunities for maximising immune engagement and activation |
| Q55191920 | Matched T cell repertoire analysis of peripheral blood and tumor-infiltrating lymphocytes (TILs) in early stage breast cancer (ESBC) patients (pts) treated with pre-operative cryoablation (cryo) and/or Ipilimumab (Ipi). |
| Q26781522 | Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs |
| Q35042668 | New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials |
| Q90598729 | Oncolysis without viruses - inducing systemic anticancer immune responses with local therapies |
| Q40696642 | Optimized magnitude of cryosurgery facilitating anti-tumor immunoreaction in a mouse model of Lewis lung cancer |
| Q36657043 | PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor |
| Q37156495 | Percutaneous irreversible electroporation for breast tissue and breast cancer: safety, feasibility, skin effects and radiologic-pathologic correlation in an animal study |
| Q36170378 | Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. |
| Q64076444 | Positive Immuno-Modulation Following Radiofrequency Assisted Liver Resection in Hepatocellular Carcinoma |
| Q54012733 | Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients. |
| Q38333001 | Re-purposing cryoablation: a combinatorial 'therapy' for the destruction of tissue |
| Q48648638 | Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors |
| Q38103582 | T-cell tolerance in cancer |
| Q64934973 | TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion. |
| Q35136450 | Targeting multiple key signaling pathways in melanoma using leelamine. |
| Q26853269 | Temperature matters! And why it should matter to tumor immunologists |
| Q38304438 | The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy |
| Q38724564 | The future of biology in driving the field of hyperthermia |
| Q42545786 | The genesis of Zelboraf: targeting mutant B-Raf in melanoma |
| Q38987399 | The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. |
| Q26751230 | Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response? |
| Q34406134 | Thermal ablation of tumours: biological mechanisms and advances in therapy. |
| Q30363372 | Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. |
| Q37246484 | Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy |
| Q39212591 | Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma |
| Q37685855 | Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer. |
Search more.